SG-001

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
JSKN003 Combined Treatment of HER2-positive Gastric Cancer	2025/05/31	NCT06998771	Phase 2	Not yet recruiting	Shanghai JMT-Bio Inc.
SYS6002 Plus JMT101 and Enlonstobart Injection as First-Line Treatment for HNSCC	2025/05/25	NCT06989671	Phase 2	Not yet recruiting	CSPC Megalith Biopharmaceutical Co.,Ltd.
A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer	2025/05/21	NCT06981858	Phase 2	Not yet recruiting	Chongqing University Cancer Hospital
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.	2024/11/11	NCT06682611	Phase 1	Not yet recruiting	Shanghai Runshi Pharmaceutical Technology Co., Ltd
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.	2023/11/18	NCT06136988	Phase 1	Not yet recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors	2023/11/15	NCT06132217	Phase 1	Not yet recruiting	Shanghai Runshi Pharmaceutical Technology Co., Ltd
A Study of JMT101 in Patients With Metastatic Colorectal Cancer	2023/10/18	NCT06089330	Phase 2	Not yet recruiting	Shanghai JMT-Bio Inc.
A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors	2022/08/19	NCT05508659	Phase 1	Not yet recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)	2021/10/05	NCT05068141	Phase 2	UNKNOWN	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer	2021/08/18	NCT05009953	Phase 2	Terminated	CSPC Ouyi Pharmaceutical Co., Ltd.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

FDA Approves ADMA Biologics' Innovative Yield Enhancement Process for Immune Globulin Production

3 months ago

ADMA Biologics has received FDA approval for a groundbreaking production process that increases immune globulin yields by approximately 20% from the same plasma volume, becoming the first U.S. company to achieve this regulatory milestone.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access